Based on the high prevalence and undiagnosed rate of diabetes mellitus in China in recent years, the aim of this work was to evaluate the availability, price and affordability of pharmacotherapy for diabetes in public hospitals in Hubei province, China. In 2016, a cross-sectional survey was conducted using World Health Organization/Health Action International (WHO/HAI) methodology. Information on the availability and prices of 20 antidiabetic drugs was collected from 34 public hospitals representing three levels of care. Of the 20 antidiabetic drugs, 70.6% were below 50% availability. Total availability of the 20 drugs was higher in secondary and tertiary hospitals than in primary hospitals. All three hospital levels had higher availability of essential than non-essential antidiabetic medicines. The median markup ratios of originator brands (OBs) and lowest-price generics (LPGs) were 15.6% and 2.1%, respectively. The median potential saving ratio of using generics was 31.3%. Overall, the median affordability of 31 antidiabetic drugs ranged from 1.2 to 8.5 days of disposable income for residents with three income levels. After insurance reimbursement, the increase in the proportion of affordable drugs in urban and rural areas averaged 35.5% and 12.9%, respectively. The proportion of drugs with low availability and low affordability dropped from 54.8% to 38.7%. However, 41.7% of urban diabetic patients and 74.0% of rural diabetic patients remained unable to afford the drugs surveyed. Higher income and generic substitution are factors facilitating affordability. In Hubei province, the overall availability of 20 antidiabetic drugs was low, especially in primary hospitals. The affordability of most drugs surveyed was also low. Current health insurance can greatly improve affordability for urban residents with middle or high income. Policy changes should focus on the supply, pricing and clinical use of antidiabetic drugs and special health insurance plan for low income population with diabetes.
Introduction
Diabetes mellitus is a chronic, progressive disease characterized by elevated blood glucose concentrations and far-reaching complications including retinopathy, neuropathy, nephropathy and cardiovascular disease. It also increases the risk of premature death. Diabetes is a life-long non-communicable disease that has become a serious threat to human health. Globally, it is estimated that 422 million people had diabetes in 2014, which was an increase from 108 million in 1980. Data from 2012 suggests that 1.5 million individuals die from the complications of diabetes annually (World Health Organization, 2016) .
Over the past decade, the prevalence of diabetes in low-and middle-income countries has risen faster than in high-income countries. The International Diabetes Federation report, (International Diabetes Federation, 2015) indicates that China has more people with diabetes (aged 20-79 years) than any other country. In 2015, this equated to 109.6 million individuals, or a prevalence of 10.6% amongst the adult Chinese population. By the year 2040, this figure is predicted to increase to 150.7 million people, equating to a prevalence of 11%. In addition to the high prevalence, China has major issues with low awareness for diabetes as a healthcare issue, underdiagnosis, low rates of treatment initiation and inadequate glycaemic control (Editor, 2014) . In one study, only one-third (33.3%) of individuals with diabetes were diagnosed and this had geographic variation . In another study, one-quarter (25.8%) of people with diabetes received treatment in 2010, and fewer than half of these (39.7%) had adequate glycaemic control (Xu et al. 2013) . Similar results also were observed in the Hubei province (Luo Wanqiao and Wensheng, 2015) .
The consequences of the high prevalence of diabetes in China together with the inadequate treatment are grave if it is considered that diabetes appears to double the risk of all-cause mortality amongst the Chinese population (Bragg et al. 2017) . Chinese individuals were also three times more likely than people in the United States of America (USA) to be hospitalized for acute diabetic complications (Alcorn and Ouyang, 2012) . Collectively, it is clear that diabetes is a heavy economic burden for China. The costs of medications to treat diabetes showed an upward trend from US$1335 to US$1383 per patient per year between 2009 and 2011 (Huang et al. 2016) . At a similar point in time, adjusted medical care expenditure for individuals with diabetes was 3.38-fold higher than for those without the disease (Yang et al. 2012) . In 2015, the total healthcare expenditure for diabetes in China was US$51 billion (International Diabetes Federation, 2015) . These costs are enormous and stand to increase with time.
Pharmacological treatment of diabetes is mainly centred upon use of oral antihyperglycaemic drugs and injectable insulin or insulin analogues, alone or in combination. In China, hospitals were central to the pharmaceutical supply chain with sales that comprise 71.4% of the retail market according to the report of Ministry of Commerce of China in 2015. It is essential that the current availability, price and affordability of antidiabetic therapies can help to identify strategies to ensure continuity of supply at a low cost for the Chinese population. Currently, available data on this topic are limited. Information from the China Hospital Drug Purchase Database of IMS (CHPA database) between 2012 and 2014 identified that recombinant human insulin (abbreviated as Rh insulin) was the dominant type of insulin used, and that the volume of insulin analogues used had increased rapidly in Chinese hospitals. The antidiabetic agents most frequently used in Chinese hospitals aligned with the national essential medicine list of China, but none were included in the World Health Organization (WHO) list (such as Novolin 30R, Humulin 70/30, 30/70 mixture Rh insulin, acarbose, glimepiride, glipizide) (Sun et al. 2016) .
Isolated reports have used WHO/HAI methodology to assess the availability, price and affordability of several antidiabetic drugs from the essential medicine list. Ewen et al. summarized 30 surveys of essential medicines conducted between 2008 and early 2015 in 30 countries. These authors found the median availability rates of four essential antidiabetic medicines (glibenclamide, metformin, insulin human and isophane 30/70, and gliclazide) in public health care facilities to range from 57.4% in low-income countries to 64.1% in upper-middle income countries including China. For OBs of antidiabetic medicines, the median affordability was 2.9 and 2.1 days' wages in low-and uppermiddle income countries, respectively. For LPGs, the comparative affordability was 0.9 and 0.3 days' wages, respectively .
In China, the mean availability of OBs and LPGs of metformin, gliclazide and glibenclamide lowered 30% in the 120 public hospitals in Shanxi province in 2012. The median monthly cost of OBs of metformin and gliclazide was 1.5 and 1.3 days' wages compared with 0.1 and 0.4 days' wages for the LPGs (Jiang et al. 2015) . In 2015, Zhu Wenwen et al. investigated the eight most commonly used oral antidiabetic drugs (metformin, glibenclamide, gliclazide, glipizide, glimepiride, acarbose and repaglinide and pioglitazone) in 72 public hospitals of Shaanxi province. Metformin and Acarbose were of the highest availability rate among generic drugs and originator drugs, 94.4% and 68.1%, respectively (Zhu Wenwen et al. 2017) . In a study of insulin supply in pharmacies in Hubei province in 2016, the mean availability of prandial, basal and pre-mixed insulin was high at 70%, 80% and 90%, respectively. However, the cost to patients of one month of treatment equated to 4 to 16 days of wages (Liu et al. 2017) .
Further work is required to extend understanding of availability, cost and affordability of antidiabetic medicines in China. The aims of this study were to determine the price and availability of 20 antidiabetic drugs across three levels of public hospitals in Hubei province, and to assess affordability using the method developed by the WHO and HAI (World Health Organization, 2008).
Key Messages
• The availability of most antidiabetic drugs surveyed was low, especially in primary hospitals.
• The median markup ratio of antidiabetic drugs is decreasing with the implementation of a zero markup ratio policy in Hubei province. The median daily cost of non-essential antidiabetic drugs could reduce by 1.36 RMB using a zero markup.
• After considering insurance reimbursement, the affordability of 31 antidiabetic drugs in urban middle and high income earners increased substantially. The proportion of drugs with low availability and low affordability has been clearly reduced.
Methods

Sampling
Hubei province has a population of 58. Table A3 ) (Wang Qi-hang and Feng-xia, 2012; Abidi et al., 2016; Sun Jing, 2016) .
Data collection and statistical analysis
For each of the 20 antidiabetic drugs, the availability and retail prices of originator brands (OBs) and lowest-price generics (LPGs) were provided by pharmacy staff working at the hospitals surveyed. Procurement prices were obtained from the drug procurement list of centralized bidding platform for public hospitals in Hubei Province (Hubei Provincial Government, 2016) . Retail price of a drug in the public hospital was made up of procurement price and markup price.
Availability evaluation and criteria
The availability of each drug is reported as the percentage of stock availability of the required drugs in the facilities on the day of data collection (WHO/HAI 2008). The following criteria were used to describe the extent of availability of antidiabetic drugs (Susanne et al. 2006; Yang et al. 2010; Gong et al. 2016 ):
• Absent (0% of hospitals): not found in any hospital surveyed • Very low (< 30% of hospitals): very difficult to find • Low (30-49% of hospitals): somewhat difficult to find • Fairly high (50-80% of hospitals): available in many hospitals • Very high (>80% of hospitals): good availability
Price criteria and evaluation
According to the WHO/HAI methodology, median prices were calculated if four or more facilities were obtained. The price markup ratio [Equation (1)] of each drug was calculated for each public hospital surveyed. This ratio was determined for each brand of the diabetic drug between the procurement platform of centralized bidding system (average procurement price) and the hospitals surveyed (average retail price). At the same time, we also calculated the potential saving ratio [Equation (2)] between the OB and LPGs.
Markup ratio ¼ ðaverage retail price -average procurement priceÞ =average procurement price Ã 100%:
(1) Potential saving ratio ¼ ðlowest price of OB -LPGÞ= lowest price of OB Ã 100%:
Assessment of affordability
According to WHO/HAI standard, drug affordability is the ability to pay for a course of treatment and is based on the daily wages of the lowest-paid unskilled government worker. If the cost of a course of treatment of an antidiabetic drug [Equation (3)] is no more than one day's wage or income, it is considered affordable.
Cost of a treatment course ¼ Defined daily dose Â P u Â Days of a treatment course:
Defined daily dose (DDD) refers to the assumed average maintenance dose per day for a drug used for its main indication in adults. We used DDD as a standard dose unit of measurement. The DDD of each drug in the study was obtained from the WHO DDD index web page (WHO Collaborating Centre for Drug Statistics Methodology, 2016). If no drug DDD of WHO definition, the DDD values of voglibose and sitagliptin were calculated according to the drug instruction and WHO principles of the assigned DDD methodology (weight 70 kg, maintenance dose). The DDD for insulin and analogues was calculated as for insulin (40 IU). P u is the unit median retail price of each drug sold in the hospitals surveyed. DDDc is the drug cost per DDD (DDDc ¼ DDD ÂP u ). The WHO also defines a treatment course for a chronic disease as 30 days.
In 2015, the lowest wage of workers in Hubei Province was 1100 RMB per month, equating to 36.7 RMB per day (US$5.7/day). Given the range of prices of antidiabetic drugs, we also selected three different income levels (lowest, middle and highest) to reflect treatment affordability for urban and rural residents. For urban residents, the lowest, middle and highest daily disposable personal incomes were 29.1, 72.1 and 147.8 RMB per day (US$4.6, US$11.3 and US$23.1 per day), respectively; for rural residents, the figures were 20.8, 35.6 and 48.5 RMB per day (US$3.2, US$5.6 and US$7.6 per day) respectively. The latter were selected from the mean net personal income of rural residents in the lowest (Shennongjia), middle (Yichang and Suizho) and highest (Wuhan) economic development areas in Hubei province.
To identify the antidiabetic drugs with wide availability and high affordability, a matrix pattern was used to display the results of the comprehensive analysis. The affordability of each drug for lowest income earners is shown on the X-axis, while the availability rate in the public hospitals is depicted on the Y-axis. Logistic regression analysis was also used to assess the relationship between affordability and influencing factors (including different areas, income levels, drug types and strengths).
Results
There were 34 responses from the 45 public hospitals surveyed (response rate of 75.6%) including 12 primary, 12 secondary and 10 tertiary hospitals.
The availability of antidiabetic drugs
Of the 20 antidiabetic drugs surveyed, glibenclamide and insulin have no OB drugs marketed in China whereas insulin aspart, sitagliptin, exenatide, liraglutide have no generic drugs marketed. Thus, the 20 antidiabetic drugs comprised 18 OBs and 16 LPGs. In the 34 public hospitals, the availability of rosiglitazone (OB and generic) and gliquidone (generic) was 0%, with a further 17 antidiabetic drugs having very low level availability (0-30%) and four having low availability (30-50%). Of the antidiabetic drugs surveyed, 24 (70.6%) had low availability (<50%) and 10 (29.4%) had a fairly high availability (50-80%). Overall, 12 of 18 OB drugs (66.7%) and 12 of 16 generic drugs (75.0%) had low or very low availability (<50%). Fairly high availability (50-80%) was found in 6 of 18 OB drugs (33.3%) and 4 of 16 generic drugs (25.0%). Supplementary Appendix Table A4 shows the availability of 20 anti-diabetic drugs in the 34 hospitals.
At the three hospital levels, the availability of 20 antidiabetic drugs was shown in Table 2 . On average, the total availability of the 20 drugs in secondary and tertiary hospitals was higher than in primary hospitals. OBs were more available than the LPGs in secondary (40.0% vs 36.8%) and tertiary hospitals (64.1% vs 48.8%). The reverse was true in primary hospitals (5.4% vs 26.8%), and overall availability was low. At the low availability level, the total availability of OBs and LPGs was 35.0% and 36.9%, respectively. Only the availability of the OBs in tertiary hospitals was at a high level (64.1%). The total availability rate of both OBs and LPGs was highest for acarbose (73.5% and 76.5%) followed by metformin (58.8% and 70.6%). Neither OB nor generic rosiglitazone was found in any hospital surveyed.
There were 11 antidiabetic drugs included in the EML of Hubei province. The total availability rate of these 11 medicines was higher than non-essential medicines in all three hospital levels. The total availability rate of essential OBs was highest in tertiary hospitals (73.1%) followed by essential OBs in secondary hospitals (53.6%) and essential LPGs in tertiary hospitals (51.7%). The total availability rate of non-essential OBs in tertiary hospitals was high (59.2%), while the others were low. The greatest difference in the availability between essential and non-essential medicines was observed in the OBs at secondary hospitals.
Price markup ratios and potential saving ratios of 18 antidiabetic drugs
Chinese drug policy required that the markup ratio in public hospitals drop from 15% to 0% in 2017. For 2016, we ascertained the markup ratio of each drug and the savings from generic substitution. We showed unit retail price and DDDc of 19 antidiabetic drugs in the hospitals surveyed in Supplementary Appendix Table A5 . Next, 18 antidiabetic drugs with the same pharmaceutical company from the procurement platform to hospitals (excluding glibenclamide) were analysed for their price markup ratios and potential saving ratios and the results are seen in Table 3 .
There were clear differences in the price markup ratios for different drugs. The median markup ratio from procurement to retail prices in the public hospital was 12.0% (range: -16.2-50%) and was much higher for OBs than for LPGs at 15.6% (1.09 RMB add-on cost per day) vs 2.1% (0.26 RMB add-on cost per day), respectively. Fifteen drugs had a >15% markup ratio, most of which were OBs (11/15, i.e. 73.3%) with the metformin OB having the highest ratio of 50%. The median markup ratio of essential antidiabetic drugs was 3.8% (range: À16.2-50%). The median add-on cost was 0.54 RMB per day overall, being 0.33 and 1.36 RMB per day for essential and non-essential antidiabetic drugs, respectively. The different retail prices for the same drug in different hospitals are largely attributed to the difference in markup ratio.
Use of generics was associated with a median potential saving ratio of 31.3% (range: À0.1-81.0%). The greatest saving ratio for LPGs was with glimepiride followed by pioglitazone and metformin. The negative potential saving ratio resulted from a unit price for LPGs that was greater than for OBs. For example, the price of repaglinide LPGs was more than the OBs because of the different dosage forms available.
Affordability at different economic levels
Because there were three drugs that were not available in any hospital surveyed, 31 out of 34 antidiabetic drugs were calculated their affordability. Table 4 shows whether the affordability of 31 antidiabetic drugs (17 OBs and 14 LPGs) exceeds the disposable income or the lowest daily wage. Overall, the median DDDc of 31 antidiabetic drugs was 5.9 RMB each day (range: 0.1-58.5 RMB). The median affordability of these drugs ranged from 1.2 to 6.1 days of disposable personal income for urban residents and from 3.7 to 8.5 days for rural residents. The monthly median cost for 31 antidiabetic drugs was unaffordable for residents of any income level.
On average, only 17.1% of these surveyed drugs were affordable to urban and rural residents. For urban residents, the mean proportion of affordable drugs out of the 31 anti-diabetic drugs was 21.5% (range: 9.7-38.7%). For rural residents, the mean proportion was 12.9% (range: 6.5-16.1%). For the workers with the lowest daily wages, 16.1% drugs (five drugs) were affordable. The median affordability was equal to 4.8 days of the lowest daily wages.
Liraglutide was the least affordable agent for both urban and rural residents. Glibenclamide and gliclazide were affordable for all residents. Five generics (glipizide, glimepiride, glibenclamide, metformin and gliclazide) were affordable for residents with middleincome and for those workers with the lowest daily wages. The OBs were less affordable than LPGs. The median affordability of LPGs was more than two times that of the OBs. The median affordability of the LPGs for urban residents with high income was less than one daily income.
Universal health insurance system was established in China in 2008. In Hubei province, this included Urban Employees' Basic Medical Insurance Scheme (UEBMIS) and Integration of Basic Medical Insurance Scheme for Urban and Rural Residents (IURBMIS). Currently, both schemes cover the same antidiabetic drugs divided into two categories referred to as 'class A' and 'class B'. Class A drugs require zero payment by patients (fully subsidized). Class B drugs require urban employees to pay 25% and general residents to pay 40% of drug costs. The affordability of each drug with different levels of insurance reimbursement is provided in Supplementary Appendix Table A6 .
After health insurance reimbursement, glipizide, glibenclamide, metformin and insulin were essentially free for all residents. The mean proportion of affordable drugs increased to 40.6%. For urban residents with three income levels from low to high, the proportion of affordable drugs increased by 19.4%, 48.4% and 38.7% Note: * in the EML of Hubei province; N, not in the EML of the Hubei province. N/A, data not available. "EM", essential medicine; "NON-EM", non-essential medicine; "Ave", average.
respectively, accounting for 29.0%, 64.5% and 77.4% of the total. For rural residents, the increases were 16.1%, 9.7% and 12.9%, reaching 22.6%, 25.8% and 29.0% of the total, respectively. The median affordability of the drugs ranged from 0.4 to 1.8 days' income for urban residents and from 1.7 to 4.0 days for rural residents. Especially, the median affordability values of middle and high-income urban residents were both <1, about 0.7 and 0.4 days' income. For the workers with the lowest daily wages, 35.5% drugs (11 drugs) were affordable. The median affordability equated to 1.4 days' wages.
For the LPGs, only the rural low-income residents showed an overall unaffordability, about 2.3 days' income. Assuming the same proportion of reimbursement for each income level, the proportion of essential medicines that were affordable for urban residents ranged from 52.9% to 88.2%. This compared with a range of 41.2% to 52.9% across the three income levels for rural residents.
The mean increase in the proportion of essential medicines that were affordable was 39.2% in urban and 23.5% rural areas, respectively (Supplementary Appendix Table A7 shows the changes in essential medicine affordability after health insurance reimbursement).
We estimated the number of individuals with diabetes at the population level, and determined that the proportion able to afford the drugs surveyed increased significantly after insurance reimbursement. In 2015, approximately 5.9 million Hubei province residents (3.6 and 2.3 million urban and rural, respectively) suffered from diabetes (Supplementary Appendix Table A8 shows the distribution of the diabetic population in Hubei province in 2015). Assuming that the quantity and distribution of the diabetes in Hubei Province in 2016 remains similar levels to those in 2015, insurance reimbursement for 2016 can enable OBs to be afforded by 1.43 million diabetic patients (40.3%) in urban areas and 0.23 million diabetic patients (10.0%) in rural areas. For the LGPs, the Table A9 shows the increase in diabetic patients with affordable medicines in Hubei province after health insurance reimbursement).
Comprehensive analysis of the availability and affordability of antidiabetic drugs
Comprehensive analysis of the availability and affordability of antidiabetic drugs is displayed by matrix pattern in Figure 1 . Quadrant I includes 2 drugs (generics of metformin and glimepiride) with high availability and high affordability, while quadrant IV includes 17 drugs (54.8%) with low availability and low affordability. Quadrant II includes nine drugs (29.0%) with high availability and low affordability, whereas quadrant III includes only three generics (glipizide, gliclazide and glibenclamide) with low availability and high affordability. 
Influencing factors of drug affordability
Logistic regression analysis examined whether affordability and unaffordability differed with area, household income, drug type or strength, or drug inclusion in an EML (Table 5) . Affordability of the antidiabetic drugs varied significantly with area (P ¼ 0.022), household income (P ¼ 0.012 and P ¼ 0.000), drug type (P ¼ 0.000) and inclusion/exclusion in an EML (P ¼ 0.030). The difference between strengths was not statistically significant (P ¼ 0.067).
In Hubei province, urban diabetic patients were 2.55-fold (95% CI 1.15-5.67) more able to afford antidiabetic drugs surveyed than rural patients. Middle-and high-income patients were 4.41-fold (95% CI 1.38-14.05) and 10.19-fold (95% CI 3.24-32.04), respectively, more able to afford antidiabetic drugs than the diabetic patients with the lowest income. Generic antidiabetic drugs, were 7.83-fold (95% CI 3.03-20.26) more affordable than OBs. Essential medicines, were 2.8-fold (95% CI 1.1-7.3) more affordable than nonessential medicines. The odds ratio suggests that high income and generics substitution are main contributors to affordability.
Discussion
We used WHO/HAI methodology to comprehensively survey the availability, price markup ratio and affordability of 20 antidiabetic drugs in the Hubei province in China. Principle findings were:
(1) Overall availability of 34 antidiabetic drugs (18 OB drugs and 16 generic drugs) was low in the surveyed hospitals, with 70.6% being below 50% availability. Availability was higher in secondary and tertiary hospitals than in primary hospitals. OBs were more available than LPGs in secondary and tertiary hospitals compared with primary hospitals. Only tertiary hospitals had fairly high OB availability. All three hospital levels had higher total availability rates for essential versus non-essential antidiabetic drugs. The basis for this low drug availability is likely multifactorial, including difference of drug lists in different hospital, availability of too many alternative drugs, a lack of incentives to maintain stock and/or inefficient supply systems (Cameron et al. 2009; Fang et al. 2013) . The high availability of OBs in tertiary hospitals may, in part, be due to the 15% markup previously permitted by the Chinese government to be added to the wholesale price. This add-on pricing policy likely encouraged the purchase of higher priced drugs. In general, the price of OBs is higher than generics, so hospitals likely prioritized procurement and use of the OBs. Additionally, physicians, pharmacists and patients are more likely to trust the quality and efficacy of OBs, and be inclined to select them when faced with more severe diabetic complications in tertiary level care. Finally, the pharmaceutical industry promotes OBs to tertiary facilities that have a higher volume of drug sales (Xi et al. 2015) .
Availability of antidiabetic drugs was lowest in primary hospitals, which can only stock essential medicines in accordance with the national essential medicine policy (NEMP) of China. The NEMP also requires all public hospitals to stock essential medicines, contributing to the overall availability of essential antidiabetic drugs in the hospitals surveyed in this study. Research from 2007 also found the availability of essential antidiabetic drugs to be extremely low in rural public and private sectors in Hubei province (Yang et al. 2010) . Our findings are consistent with another research that showed the availability of OBs and LPGs of eight oral antidiabetic drugs to be lowest in community health service centres, while OBs were most available in tertiary hospitals (Zhu Wenwen et al. 2017) .
The availability of essential antidiabetic medicines in Hubei province was relatively low compared with Sri Lanka. We found metformin, acarbose and generics of human insulin had fairly high (50-80%) availability whereas gliclazide, glibenclamide and protamine Rh insulin had low availability (<50%). In the public health sector in Sri Lanka, glibenclamide had a high availability (>80%) while metformin, insulin human and intermediate-acting insulin had fairly high availability (50-80%) and only gliclazide had very low availability (<30%) (Dabare et al. 2014) .
To facilitate availability of the 20 antidiabetic drugs, procurement lists for provincial and hospital drugs should be adjusted to match standard treatment guidelines for diabetes. This improvement would promote purchasing efficiency (Cameron et al. 2009 ), transparency of the drug bidding system and regular monitoring of the distribution chain as well as encouraging the use of essential medicines. There should also be some incentives to promote the availability of antidiabetic drugs in primary hospitals.
(2) Median markup ratio from procurement to retail prices in public hospitals was 12.0% (range: À16.2-50%), and higher for OBs than LPGs. The variation in markup ratio in the different hospitals surveyed resulted in the different retail prices for the same drug.
In 2007, Yang et al. reported a median markup of 44.8% (range: 15.6-177.8%) for 39 essential medicines collected from 18 public hospitals and 18 private pharmacies in rural Hubei province (Yang et al. 2010) . In 2010, Jiang et al. described the median markup as 15.1% (range: 0-80%) for 46 essential medicines collected from 50 public and 36 private sector medicine outlets in six regions of Shaanxi province (Jiang et al. 2013) . Our study indicates that the median markup ratio of drugs (as judged by antidiabetic drugs) is declining, and is now <15%.
In August 2015, the Hubei province Health and Family Planning Commission piloted a 'zero-markup' policy in some hospitals. Prior to this, hospitals in Hubei province varied in their approach, with only some having a 'zero-markup' policy. Our study determined that there were four drugs with zero markups (acarbose, gliquidone, metformin and nateglinide). Glimepiride and insulin had a negative markup ratio, meaning that the retail prices of these two drugs in some of the hospitals surveyed were lower than the procurement prices of the bidding platform in 2016. Elimination of the markup ratio could reduce the median daily cost of non-essential drugs by 1.36 RMB.
Our study also showed generic substitution could lighten cost to patients. The median potential saving ratio of using generics was 31.3%. The affordability of LPGs was about eight times higher than that of the OBs. Future policy should ensure the quality of generic drugs as well as promote their use by healthcare providers and patients. Additionally, market competition or price negotiation could also facilitate a reduction in OB price.
(3) Most of antidiabetic drugs surveyed are unaffordable for most residents in the absence of health insurance reimbursement. The advent of universal health insurance has led to a dramatic increase in the affordability of 31 antidiabetic drugs in Hubei province. The mean increase in the proportion of affordable drugs was 23.5% (35.5% in urban areas and 12.9% in rural areas). Median cost to these residents of one month of treatment was already below the income of one day. Only the rural low-income residents still showed an overall unaffordability. However, the low-income group in the rural areas had the greatest increase (29.4%) in the proportion of essential medicines able to be afforded. In addition, the proportion of drugs with low availability and low affordability dropped from 54.8% to 38.7%. High income and generic alternatives are major factors facilitating affordability. To further analyse affordability, disposable personal income and the lowest day's wage were considered for urban and rural areas. Differences in drug affordability were observed among different income levels and different areas. On average, disposable personal income in urban areas is twice that seen in rural areas. Universal health insurance increased greatly the affordability of 31 antidiabetic drugs for urban middle and high income earners. However, there were still about 1.5 million diabetic patients (41.7%) in urban areas and 1.7 million diabetic patients (74.0%) in rural areas who cannot afford the antidiabetic drugs surveyed in 2016. Policy changes are needed to address the inequity in affordability of antidiabetic drugs between rich and poor, and between urban and rural areas.
Conclusion
In Hubei province, the total availability of most of antidiabetic drugs surveyed was low, especially in primary hospitals. The median affordability of most antidiabetic drugs was low for the majority of individuals in the absence of health insurance. After insurance reimbursement, drug affordability of diabetic patients was improved significantly. Strategies need direct toward lowering prices and improving the health insurance coverage. In the future, an integrated policy design for antidiabetic drugs should be given more attention, including adjusting current procurement list of drugs, promoting the zero markup price policy, encouraging the prescriptions of generics and essential medicines, securing adequate drug supplies in primary hospitals and improving the insurance reimbursement level for low income population. More research should focus on the availability and affordability of antidiabetic drugs at the household and individual level.
Limitation
In order to improve the achievability of hospital survey, we chose to conduct this survey for 20 antidiabetic drugs. However, it is not exhaustive and leaves out some high use agents such as insulin detemir. We also collected data on a single day for the particular hospital surveyed (a snapshot), and accept that the data will potentially be subject to external variation, such as market fluctuations, the implementation of zero-markup policy and supply schedules. Some data were unavailable. Overall availability of the antidiabetic drugs may be overestimated because of the different ratio of public hospital types. In Hubei provinces in 2015, there were 235 primary hospitals, 266 secondary hospitals and 121 tertiary hospitals (1.9:2.2:1). About >90% of outpatient and inpatient visits took place in public hospitals. Therefore, we did not consider private hospitals nor did not reflect upon the availability of antidiabetic drugs in all of the hospitals in Hubei Province. Finally, affordability may be overestimated as it includes drug costs only and fails to consider other costs such as diagnostic tests, management of the complications of treatment or use of more than one antidiabetic agent at a time.
Supplementary Data
Supplementary data are available at Health Policy and Planning online.
